Back to Search
Start Over
Synthesis and pharmacological evaluation of potent and enantioselective sigma 1, and sigma 2 ligands.
- Source :
-
Farmaco (Societa chimica italiana : 1989) [Farmaco] 2001 Mar; Vol. 56 (3), pp. 181-9. - Publication Year :
- 2001
-
Abstract
- In a previous study we found that substitutions of the (+)-cis-N-normetazocine nucleus of (+)-MPCB with 1-adamantanamine provide the compound (+/-)-10 with high affinity and selectivity for sigma receptors. Starting with this result we have synthesized a new series of eight 1-phenyl-2-cyclopropylmethylamines structurally related to (+/-)-10, and binding affinities, with respect to sigma 1, sigma 2, opioid and dopaminergic D2 receptors, have been reported. All compounds showed a negligible opioid and dopaminergic affinity and high selectivity for sigma receptors. Modifications on the amino moiety and methylcarboxyester group of 10 provide compounds with different sigma 1 and sigma 2 binding affinity and selectivity. Moreover, we have also synthesized the respective enantiomers of componds (+/-)-10 and (+/-)-18 in order to evaluate the enantioselectivity for sigma 1 and sigma 2 receptors. The binding data showed that carboxymethylester on the cyclopropane ring was more critical for enantioselectivity than the hydroxymethylenic group. In fact, the (-)-10 enantiomer showed a preference for sigma 1 whereas (+)-10 showed a preference for sigma 2.
- Subjects :
- Amino Acid Sequence
Humans
Ligands
Molecular Sequence Data
Receptors, Dopamine D2 drug effects
Stereoisomerism
Sigma-1 Receptor
Analgesics, Opioid chemical synthesis
Analgesics, Opioid pharmacology
Cyclazocine analogs & derivatives
Cyclazocine chemical synthesis
Cyclazocine pharmacology
Receptors, sigma drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 0014-827X
- Volume :
- 56
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Farmaco (Societa chimica italiana : 1989)
- Publication Type :
- Academic Journal
- Accession number :
- 11409325
- Full Text :
- https://doi.org/10.1016/s0014-827x(01)01039-4